Drug Profile
UCART 22
Alternative Names: UCART-22Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Cellectis
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 09 Dec 2023 Updated efficacy and adverse events data from phase I/II BALLI-01 trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Nov 2023 Updated efficacy and adverse events data from the BALLI_01 phase-I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma released by Cellectis
- 09 Jun 2023 Updated efficacy and adverse event data from a phase I/IIa trial in Precursor B-cell lymphoblastic leukaemia-lymphoma released by Cellectis